The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises
The yes-associated protein (YAP) and the transcriptional coactivator with PDZ-binding motif (TAZ) are transcriptional coactivators, members of the Hippo signaling pathway, which play a critical role in cell growth regulation, embryonic development, regeneration, proliferation, and cancer origin and...
- Autores:
-
Ortega, Ángel
Vera, Ivana
Diaz, Maria P.
Navarro, Carla
Rojas, Milagros
Torres, Wheeler
Parra, Heliana
Salazar, Juan
De Sanctis, Juan B.
Bermúdez, Valmore
- Tipo de recurso:
- Fecha de publicación:
- 2022
- Institución:
- Universidad Simón Bolívar
- Repositorio:
- Repositorio Digital USB
- Idioma:
- eng
- OAI Identifier:
- oai:bonga.unisimon.edu.co:20.500.12442/9506
- Palabra clave:
- YAP/TAZ
Hippo signaling pathway
carcinogenesis
Tumor microenvironment
neoplastic stem cells
cell proliferation
drug resistance
chemoresistance
immunotherapy
- Rights
- openAccess
- License
- Attribution-NonCommercial-NoDerivatives 4.0 Internacional
| id |
USIMONBOL2_6765bc298d39f89f1d26b0bdb1c48663 |
|---|---|
| oai_identifier_str |
oai:bonga.unisimon.edu.co:20.500.12442/9506 |
| network_acronym_str |
USIMONBOL2 |
| network_name_str |
Repositorio Digital USB |
| repository_id_str |
|
| dc.title.eng.fl_str_mv |
The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises |
| title |
The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises |
| spellingShingle |
The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises YAP/TAZ Hippo signaling pathway carcinogenesis Tumor microenvironment neoplastic stem cells cell proliferation drug resistance chemoresistance immunotherapy |
| title_short |
The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises |
| title_full |
The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises |
| title_fullStr |
The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises |
| title_full_unstemmed |
The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises |
| title_sort |
The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises |
| dc.creator.fl_str_mv |
Ortega, Ángel Vera, Ivana Diaz, Maria P. Navarro, Carla Rojas, Milagros Torres, Wheeler Parra, Heliana Salazar, Juan De Sanctis, Juan B. Bermúdez, Valmore |
| dc.contributor.author.none.fl_str_mv |
Ortega, Ángel Vera, Ivana Diaz, Maria P. Navarro, Carla Rojas, Milagros Torres, Wheeler Parra, Heliana Salazar, Juan De Sanctis, Juan B. Bermúdez, Valmore |
| dc.subject.eng.fl_str_mv |
YAP/TAZ Hippo signaling pathway carcinogenesis Tumor microenvironment neoplastic stem cells cell proliferation drug resistance chemoresistance immunotherapy |
| topic |
YAP/TAZ Hippo signaling pathway carcinogenesis Tumor microenvironment neoplastic stem cells cell proliferation drug resistance chemoresistance immunotherapy |
| description |
The yes-associated protein (YAP) and the transcriptional coactivator with PDZ-binding motif (TAZ) are transcriptional coactivators, members of the Hippo signaling pathway, which play a critical role in cell growth regulation, embryonic development, regeneration, proliferation, and cancer origin and progression. The mechanism involves the nuclear binding of the un-phosphorylated YAP/TAZ complex to release the transcriptional enhanced associate domain (TEAD) from its repressors. The active ternary complex is responsible for the aforementioned biological effects. Overexpression of YAP/TAZ has been reported in cancer stem cells and tumor resistance. The resistance involves chemotherapy, targeted therapy, and immunotherapy. This review provides an overview of YAP/TAZ pathways’ role in carcinogenesis and tumor microenvironment. Potential therapeutic alternatives are also discussed. |
| publishDate |
2022 |
| dc.date.accessioned.none.fl_str_mv |
2022-04-01T18:28:42Z |
| dc.date.available.none.fl_str_mv |
2022-04-01T18:28:42Z |
| dc.date.issued.none.fl_str_mv |
2022 |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.driver.eng.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.spa.spa.fl_str_mv |
Artículo científico |
| dc.identifier.citation.eng.fl_str_mv |
Ortega, Á.; Vera, I.; Diaz, M.P.; Navarro, C.; Rojas, M.; Torres, W.; Parra, H.; Salazar, J.; Sanctis, J.B.D.; Bermúdez, V. The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises. Int. J. Mol. Sci. 2022, 23, 430. https://doi.org/ 10.3390/ijms23010430 |
| dc.identifier.issn.none.fl_str_mv |
14220067 |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/20.500.12442/9506 |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.3390/ijms23010430 |
| identifier_str_mv |
Ortega, Á.; Vera, I.; Diaz, M.P.; Navarro, C.; Rojas, M.; Torres, W.; Parra, H.; Salazar, J.; Sanctis, J.B.D.; Bermúdez, V. The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises. Int. J. Mol. Sci. 2022, 23, 430. https://doi.org/ 10.3390/ijms23010430 14220067 |
| url |
https://hdl.handle.net/20.500.12442/9506 https://doi.org/10.3390/ijms23010430 |
| dc.language.iso.eng.fl_str_mv |
eng |
| language |
eng |
| dc.rights.*.fl_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 Internacional |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.rights.accessrights.eng.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.mimetype.spa.fl_str_mv |
pdf |
| dc.publisher.spa.fl_str_mv |
MDPI |
| dc.source.eng.fl_str_mv |
International Journal of Molecular Sciences |
| dc.source.none.fl_str_mv |
Vol. 23, No. 1 (2022) |
| institution |
Universidad Simón Bolívar |
| bitstream.url.fl_str_mv |
https://bonga.unisimon.edu.co/bitstreams/aaffa76f-4475-47d3-b60b-5b0b1b628443/download https://bonga.unisimon.edu.co/bitstreams/4f95f664-b3d2-4c78-a4a5-dba97310be47/download https://bonga.unisimon.edu.co/bitstreams/1f5e025a-5f3d-4d7e-8b5b-6f0c1b4212b6/download https://bonga.unisimon.edu.co/bitstreams/389239b0-8bab-4ded-8560-eac86ae97031/download https://bonga.unisimon.edu.co/bitstreams/6e8ef8e0-f974-48b3-8ddb-5fb1cf69e5e5/download https://bonga.unisimon.edu.co/bitstreams/790c4a40-c89b-476f-8e69-bceaf71a7afe/download https://bonga.unisimon.edu.co/bitstreams/31698fad-7253-43ba-b831-d6f5cdb23649/download |
| bitstream.checksum.fl_str_mv |
af1ff5187ee695af002b5ddcdcee391c 4460e5956bc1d1639be9ae6146a50347 733bec43a0bf5ade4d97db708e29b185 d1783533cb1d1a9ffedda66103eb1e9c d1783533cb1d1a9ffedda66103eb1e9c 855982823cd0f2932777ffb10b0a7a51 855982823cd0f2932777ffb10b0a7a51 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Digital Universidad Simón Bolívar |
| repository.mail.fl_str_mv |
repositorio.digital@unisimon.edu.co |
| _version_ |
1812100502403416064 |
| spelling |
Ortega, Ángelb6a809bb-4d26-4e53-9419-e4eb9fb40a9bVera, Ivana89ef899e-d9fb-4348-b1ff-f1b3543f4019Diaz, Maria P.14ead2c3-89e6-4410-ab5e-0b5697302235Navarro, Carla9892bf34-10a9-479a-8b3a-6769d4804207Rojas, Milagrosd07a9d4d-cce2-438c-b4a0-fc5ed4af1a67Torres, Wheelera82c8c05-2160-44dc-b397-ffc2ac51becaParra, Heliana13603b25-99ce-42ac-a469-5b65a89ce794Salazar, Juanfbd053e7-5aea-424c-812f-92153ecb9181De Sanctis, Juan B.ca98a00e-c126-4f97-bdb0-a08c25ad8c59Bermúdez, Valmore29f9aa18-16a4-4fd3-8ce5-ed94a0b8663a2022-04-01T18:28:42Z2022-04-01T18:28:42Z2022Ortega, Á.; Vera, I.; Diaz, M.P.; Navarro, C.; Rojas, M.; Torres, W.; Parra, H.; Salazar, J.; Sanctis, J.B.D.; Bermúdez, V. The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises. Int. J. Mol. Sci. 2022, 23, 430. https://doi.org/ 10.3390/ijms2301043014220067https://hdl.handle.net/20.500.12442/9506https://doi.org/10.3390/ijms23010430The yes-associated protein (YAP) and the transcriptional coactivator with PDZ-binding motif (TAZ) are transcriptional coactivators, members of the Hippo signaling pathway, which play a critical role in cell growth regulation, embryonic development, regeneration, proliferation, and cancer origin and progression. The mechanism involves the nuclear binding of the un-phosphorylated YAP/TAZ complex to release the transcriptional enhanced associate domain (TEAD) from its repressors. The active ternary complex is responsible for the aforementioned biological effects. Overexpression of YAP/TAZ has been reported in cancer stem cells and tumor resistance. The resistance involves chemotherapy, targeted therapy, and immunotherapy. This review provides an overview of YAP/TAZ pathways’ role in carcinogenesis and tumor microenvironment. Potential therapeutic alternatives are also discussed.pdfengMDPIAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2International Journal of Molecular SciencesVol. 23, No. 1 (2022)YAP/TAZHippo signaling pathwaycarcinogenesisTumor microenvironmentneoplastic stem cellscell proliferationdrug resistancechemoresistanceimmunotherapyThe YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promisesinfo:eu-repo/semantics/articleArtículo científicohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_2df8fbb1Ferlay, J.; Colombet, M.; Soerjomataram, I.; Parkin, D.M.; Piñeros, M.; Znaor, A.; Bray, F. Cancer Statistics for the Year 2020: An Overview. Int. J. Cancer 2021, 149, 778–789Bizzarri, M.; Cucina, A. Tumor and the Microenvironment: A Chance to Reframe the Paradigm of Carcinogenesis? BioMed Res. Int. 2014, 2014, e934038Hanahan, D.; Coussens, L.M. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment. Cancer Cell 2012, 21, 309–322Sanchez-Vega, F.; Mina, M.; Armenia, J.; Chatila, W.K.; Luna, A.; La, K.C.; Dimitriadoy, S.; Liu, D.L.; Kantheti, H.S.; Saghafinia, S.; et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell 2018, 173, 321–337.e10.Sever, R.; Brugge, J.S. Signal Transduction in Cancer. Cold Spring Harb. Perspect. Med. 2015, 5, a006098Yu, F.-X.; Zhao, B.; Guan, K.-L. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell 2015, 163, 811–828Chen, Y.; Han, H.; Seo, G.; Vargas, R.E.; Yang, B.; Chuc, K.; Zhao, H.; Wang, W. Systematic Analysis of the Hippo Pathway Organization and Oncogenic Alteration in Evolution. Sci. Rep. 2020, 10, 3173.Hansen, C.G.; Moroishi, T.; Guan, K.-L. YAP and TAZ: A Nexus for Hippo Signaling and Beyond. Trends Cell Biol. 2015, 25, 499–513Pobbati, A.V.; Hong, W. A Combat with the YAP/TAZ-TEAD Oncoproteins for Cancer Therapy. Theranostics 2020, 10, 3622–3635Omori, H.; Nishio, M.; Masuda, M.; Miyachi, Y.; Ueda, F.; Nakano, T.; Sato, K.; Mimori, K.; Taguchi, K.; Hikasa, H.; et al. YAP1 Is a Potent Driver of the Onset and Progression of Oral Squamous Cell Carcinoma. Sci. Adv. 2020, 6, eaay3324.Canu, V.; Donzelli, S.; Sacconi, A.; Lo Sardo, F.; Pulito, C.; Bossel, N.; Di Benedetto, A.; Muti, P.; Botti, C.; Domany, E.; et al. Aberrant Transcriptional and Post-Transcriptional Regulation of SPAG5, a YAP-TAZ-TEAD Downstream Effector, Fuels Breast Cancer Cell Proliferation. Cell Death Differ. 2021, 28, 1493–1511.Shreberk-Shaked, M.; Dassa, B.; Sinha, S.; Di Agostino, S.; Azuri, I.; Mukherjee, S.; Aylon, Y.; Blandino, G.; Ruppin, E.; Oren, M. A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer. Cancer Res. 2020, 80, 4145–4157.Zanconato, F.; Battilana, G.; Forcato, M.; Filippi, L.; Azzolin, L.; Manfrin, A.; Quaranta, E.; Di Biagio, D.; Sigismondo, G.; Guzzardo, V.; et al. Transcriptional Addiction in Cancer Cells Is Mediated by YAP/TAZ through BRD4. Nat. Med. 2018, 24, 1599–1610Ferrari, N.; Ranftl, R.; Chicherova, I.; Slaven, N.D.; Moeendarbary, E.; Farrugia, A.J.; Lam, M.; Semiannikova, M.; Westergaard, M.C.W.; Tchou, J.; et al. Dickkopf-3 Links HSF1 and YAP/TAZ Signalling to Control Aggressive Behaviours in Cancer-Associated Fibroblasts. Nat. Commun. 2019, 10, 130.Lopez-Hernandez, A.; Sberna, S.; Campaner, S. Emerging Principles in the Transcriptional Control by YAP and TAZ. Cancers 2021, 13, 4242Varelas, X. The Hippo Pathway Effectors TAZ and YAP in Development, Homeostasis and Disease. Development 2014, 141, 1614–1626.Plouffe, S.W.; Meng, Z.; Lin, K.C.; Lin, B.; Hong, A.W.; Chun, J.V.; Guan, K.-L. Characterization of Hippo Pathway Components by Gene Inactivation. Mol. Cell. 2016, 64, 993–1008.Liu, H.; Du, S.; Lei, T.; Wang, H.; He, X.; Tong, R.; Wang, Y. Multifaceted Regulation and Functions of YAP/TAZ in Tumors (Review). Oncol. Rep. 2018, 40, 16–28.Fu, V.; Plouffe, S.W.; Guan, K.-L. The Hippo Pathway in Organ Development, Homeostasis, and Regeneration. Curr. Opin. Cell Biol. 2017, 49, 99–107Maugeri-Saccà, M.; De Maria, R. The Hippo Pathway in Normal Development and Cancer. Pharmacol. Ther. 2018, 186, 60–72Gumbiner, B.M.; Kim, N.-G. The Hippo-YAP Signaling Pathway and Contact Inhibition of Growth. J. Cell Sci. 2014, 127, 709–717Pan, D. The Hippo Signaling Pathway in Development and Cancer. Dev. Cell 2010, 19, 491–505Kim, Y.; Jho, E.-H. Regulation of the Hippo Signaling Pathway by Ubiquitin Modification. BMB Rep. 2018, 51, 143–150Kim, Y.; Jho, E.-H. Regulation of the Hippo Signaling Pathway by Ubiquitin Modification. BMB Rep. 2018, 51, 143–150Misra, J.R.; Irvine, K.D. The Hippo Signaling Network and Its Biological Functions. Annu. Rev. Genet. 2018, 52, 65–87.Kim, C.-L.; Choi, S.-H.; Mo, J.-S. Role of the Hippo Pathway in Fibrosis and Cancer. Cells 2019, 8, E468Calses, P.C.; Crawford, J.J.; Lill, J.R.; Dey, A. Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities. Trends Cancer 2019, 5, 297–307Santucci, M.; Vignudelli, T.; Ferrari, S.; Mor, M.; Scalvini, L.; Bolognesi, M.L.; Uliassi, E.; Costi, M.P. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment. J. Med. Chem. 2015, 58, 4857–4873Chen, Y.-A.; Lu, C.-Y.; Cheng, T.-Y.; Pan, S.-H.; Chen, H.-F.; Chang, N.-S. WW Domain-Containing Proteins YAP and TAZ in the Hippo Pathway as Key Regulators in Stemness Maintenance, Tissue Homeostasis, and Tumorigenesis. Front. Oncol. 2019, 9, 60Zanconato, F.; Cordenonsi, M.; Piccolo, S. YAP/TAZ at the Roots of Cancer. Cancer Cell 2016, 29, 783–803Debaugnies, M.; Sánchez-Danés, A.; Rorive, S.; Raphaël, M.; Liagre, M.; Parent, M.-A.; Brisebarre, A.; Salmon, I.; Blanpain, C. YAP and TAZ Are Essential for Basal and Squamous Cell Carcinoma Initiation. EMBO Rep. 2018, 19, e45809.Hagenbeek, T.J.; Webster, J.D.; Kljavin, N.M.; Chang, M.T.; Pham, T.; Lee, H.-J.; Klijn, C.; Cai, A.G.; Totpal, K.; Ravishankar, B.; et al. The Hippo Pathway Effector TAZ Induces TEAD-Dependent Liver Inflammation and Tumors. Sci. Signal. 2018, 11, eaaj1757.Zhou, X.; Lei, Q.-Y. Regulation of TAZ in Cancer. Protein Cell 2016, 7, 548–561Park, H.W.; Kim, Y.C.; Yu, B.; Moroishi, T.; Mo, J.-S.; Plouffe, S.W.; Meng, Z.; Lin, K.C.; Yu, F.-X.; Alexander, C.M.; et al. Alternative Wnt Signaling Activates YAP/TAZ. Cell 2015, 162, 780–794Lim, S.K.; Lu, S.Y.; Kang, S.-A.; Tan, H.J.; Li, Z.; Wee, Z.N.A.; Guan, J.S.; Reddy Chichili, V.P.; Sivaraman, J.; Putti, T.; et al. Wnt Signaling Promotes Breast Cancer by Blocking ITCH-Mediated Degradation of YAP/TAZ Transcriptional Coactivator WBP2. Cancer Res. 2016, 76, 6278–6289Bisso, A.; Filipuzzi, M.; Gamarra Figueroa, G.P.; Brumana, G.; Biagioni, F.; Doni, M.; Ceccotti, G.; Tanaskovic, N.; Morelli, M.J.; Pendino, V.; et al. Cooperation Between MYC and β-Catenin in Liver Tumorigenesis Requires Yap/Taz. Hepatology 2020, 72, 1430–1443Park, J.H.; Shin, J.E.; Park, H.W. The Role of Hippo Pathway in Cancer Stem Cell Biology. Mol. Cells 2018, 41, 83–92.Park, J.H.; Shin, J.E.; Park, H.W. The Role of Hippo Pathway in Cancer Stem Cell Biology. Mol. Cells 2018, 41, 83–92.Zanconato, F.; Forcato, M.; Battilana, G.; Azzolin, L.; Quaranta, E.; Bodega, B.; Rosato, A.; Bicciato, S.; Cordenonsi, M.; Piccolo, S. Genome-Wide Association between YAP/TAZ/TEAD and AP-1 at Enhancers Drives Oncogenic Growth. Nat. Cell Biol. 2015, 17, 1218–1227.Pocaterra, A.; Romani, P.; Dupont, S. YAP/TAZ Functions and Their Regulation at a Glance. J. Cell Sci. 2020, 133, jcs230425.Pocaterra, A.; Romani, P.; Dupont, S. YAP/TAZ Functions and Their Regulation at a Glance. J. Cell Sci. 2020, 133, jcs230425.Koo, J.H.; Guan, K.-L. Interplay between YAP/TAZ and Metabolism. Cell Metab. 2018, 28, 196–206.Da Silva-Diz, V.; Lorenzo-Sanz, L.; Bernat-Peguera, A.; Lopez-Cerda, M.; Muñoz, P. Cancer Cell Plasticity: Impact on Tumor Progression and Therapy Response. Semin. Cancer Biol. 2018, 53, 48–58.Merrell, A.J.; Stanger, B.Z. Adult Cell Plasticity in Vivo: De-Differentiation and Transdifferentiation Are Back in Style. Nat. Rev. Mol. Cell Biol. 2016, 17, 413–425Le Magnen, C.; Shen, M.M.; Abate-Shen, C. Lineage Plasticity in Cancer Progression and Treatment. Annu. Rev. Cancer Biol. 2018, 2, 271–289.Piccolo, S.; Dupont, S.; Cordenonsi, M. The Biology of YAP/TAZ: Hippo Signaling and Beyond. Physiol. Rev. 2014, 94, 1287–1312Panciera, T.; Azzolin, L.; Fujimura, A.; Di Biagio, D.; Frasson, C.; Bresolin, S.; Soligo, S.; Basso, G.; Bicciato, S.; Rosato, A.; et al. Induction of Expandable Tissue-Specific Stem/Progenitor Cells through Transient Expression of YAP/TAZ. Cell Stem Cell 2016, 19, 725–737.Cordenonsi, M.; Zanconato, F.; Azzolin, L.; Forcato, M.; Rosato, A.; Frasson, C.; Inui, M.; Montagner, M.; Parenti, A.R.; Poletti, A.; et al. The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells. Cell 2011, 147, 759–772.Gil, J.; Rodriguez, T. Cancer: The Transforming Power of Cell Competition. Curr. Biol. 2016, 26, R164–R166Bowling, S.; Lawlor, K.; Rodríguez, T.A. Cell Competition: The Winners and Losers of Fitness Selection. Development 2019, 146, dev167486.uijkerbuijk, S.J.E.; Kolahgar, G.; Kucinski, I.; Piddini, E. Cell Competition Drives the Growth of Intestinal Adenomas in Drosophila. Curr. Biol. 2016, 26, 428–438Liu, Z.; Yee, P.P.; Wei, Y.; Liu, Z.; Kawasawa, Y.I.; Li, W. Differential YAP Expression in Glioma Cells Induces Cell Competition and Promotes Tumorigenesis. J. Cell Sci. 2019, 132, jcs225714.Seager, R.J.; Hajal, C.; Spill, F.; Kamm, R.D.; Zaman, M.H. Dynamic Interplay between Tumour, Stroma and Immune System Can Drive or Prevent Tumour Progression. Converg. Sci. Phys. Oncol. 2017, 3, 034002Balkwill, F.R.; Capasso, M.; Hagemann, T. The Tumor Microenvironment at a Glance. J. Cell Sci. 2012, 125, 5591–5596.Wei, R.; Liu, S.; Zhang, S.; Min, L.; Zhu, S. Cellular and Extracellular Components in Tumor Microenvironment and Their Application in Early Diagnosis of Cancers. Anal. Cell. Pathol. 2020, 2020, 6283796.Franco, P.I.R.; Rodrigues, A.P.; De Menezes, L.B.; Miguel, M.P. Tumor Microenvironment Components: Allies of Cancer Progression. Pathol. Res. Pract. 2020, 216, 152729.Piccolo, S.; Cordenonsi, M.; Dupont, S. Molecular Pathways: YAP and TAZ Take Center Stage in Organ Growth and Tumorigenesis. Clin. Cancer Res. 2013, 19, 4925–4930.Boopathy, G.T.K.; Hong, W. Role of Hippo Pathway-YAP/TAZ Signaling in Angiogenesis. Front. Cell Dev. Biol. 2019, 7, 49.White, S.M.; Murakami, S.; Yi, C. The Complex Entanglement of Hippo-Yap/Taz Signaling in Tumor Immunity. Oncogene 2019, 38, 2899–2909Pan, Z.; Tian, Y.; Cao, C.; Niu, G. The Emerging Role of YAP/TAZ in Tumor Immunity. Mol. Cancer Res. 2019, 17, 1777–1786.Horsman, M.R.; Vaupel, P. Pathophysiological Basis for the Formation of the Tumor Microenvironment. Front. Oncol. 2016, 6, 66.Mittal, V. Epithelial Mesenchymal Transition in Tumor Metastasis. Annu. Rev. Pathol. 2018, 13, 395–412Prieto-García, E.; Díaz-García, C.V.; García-Ruiz, I.; Agulló-Ortuño, M.T. Epithelial-to-Mesenchymal Transition in Tumor Progression. Med. Oncol. 2017, 34, 122.Redfern, A.D.; Spalding, L.J.; Thompson, E.W. The Kraken Wakes: Induced EMT as a Driver of Tumour Aggression and Poor Outcome. Clin. Exp. Metastasis 2018, 35, 285–308.Bhatia, S.; Wang, P.; Toh, A.; Thompson, E.W. New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression. Front. Mol. Biosci. 2020, 7, 71Pei, D.; Shu, X.; Gassama-Diagne, A.; Thiery, J.P. Mesenchymal-Epithelial Transition in Development and Reprogramming. Nat. Cell Biol. 2019, 21, 44–53.ang, J.; Antin, P.; Berx, G.; Blanpain, C.; Brabletz, T.; Bronner, M.; Campbell, K.; Cano, A.; Casanova, J.; Christofori, G.; et al. Guidelines and Definitions for Research on Epithelial-Mesenchymal Transition. Nat. Rev. Mol. Cell Biol. 2020, 21, 341–352.Aiello, N.M.; Kang, Y. Context-Dependent EMT Programs in Cancer Metastasis. J. Exp. Med. 2019, 216, 1016–1026.Li, Z.; Wang, Y.; Zhu, Y.; Yuan, C.; Wang, D.; Zhang, W.; Qi, B.; Qiu, J.; Song, X.; Ye, J.; et al. The Hippo Transducer TAZ Promotes Epithelial to Mesenchymal Transition and Cancer Stem Cell Maintenance in Oral Cancer. Mol. Oncol. 2015, 9, 1091–1105Ling, H.-H.; Kuo, C.-C.; Lin, B.-X.; Huang, Y.-H.; Lin, C.-W. Elevation of YAP Promotes the Epithelial-Mesenchymal Transition and Tumor Aggressiveness in Colorectal Cancer. Exp. Cell Res. 2017, 350, 218–225.Diepenbruck, M.; Waldmeier, L.; Ivanek, R.; Berninger, P.; Arnold, P.; Van Nimwegen, E.; Christofori, G. Tead2 Expression Levels Control the Subcellular Distribution of Yap and Taz, Zyxin Expression and Epithelial-Mesenchymal Transition. J. Cell Sci. 2014, 127, 1523–1536Zhou, H.; Li, G.; Huang, S.; Feng, Y.; Zhou, A. SOX9 Promotes Epithelial-Mesenchymal Transition via the Hippo-YAP Signaling Pathway in Gastric Carcinoma Cells. Oncol. Lett. 2019, 18, 599–608.Chen, G.; Xie, J.; Huang, P.; Yang, Z. Overexpression of TAZ Promotes Cell Proliferation, Migration and Epithelial-Mesenchymal Transition in Ovarian Cancer. Oncol. Lett. 2016, 12, 1821–1825.Wang, Q.; Xu, Z.; An, Q.; Jiang, D.; Wang, L.; Liang, B.; Li, Z. TAZ Promotes Epithelial to Mesenchymal Transition via the Upregulation of Connective Tissue Growth Factor Expression in Neuroblastoma Cells. Mol Med. Rep. 2015, 11, 982–988.Cheng, D.; Jin, L.; Chen, Y.; Xi, X.; Guo, Y. YAP Promotes Epithelial Mesenchymal Transition by Upregulating Slug Expression in Human Colorectal Cancer Cells. Int. J. Clin. Exp. Pathol. 2020, 13, 701–710.Franzetti, G.-A.; Laud-Duval, K.; Van der Ent, W.; Brisac, A.; Irondelle, M.; Aubert, S.; Dirksen, U.; Bouvier, C.; De Pinieux, G.; Snaar-Jagalska, E.; et al. Cell-to-Cell Heterogeneity of EWSR1-FLI1 Activity Determines Proliferation/Migration Choices in Ewing Sarcoma Cells. Oncogene 2017, 36, 3505–3514.Kovar, H.; Bierbaumer, L.; Radic-Sarikas, B. The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis. Cells 2020, 9, E972.Piccolo, S.; Cordenonsi, M. Regulation of YAP and TAZ by Epithelial Plasticity. In The Hippo Signaling Pathway and Cancer; Oren, M., Aylon, Y., Eds.; Springer: New York, NY, USA, 2013; pp. 89–113. ISBN 978-1-4614-6219-4Yamaguchi, H.; Taouk, G.M. A Potential Role of YAP/TAZ in the Interplay Between Metastasis and Metabolic Alterations. Front. Oncol. 2020, 10, 928.Viallard, C.; Larrivée, B. Tumor Angiogenesis and Vascular Normalization: Alternative Therapeutic Targets. Angiogenesis 2017, 20, 409–426Zuazo-Gaztelu, I.; Casanovas, O. Unraveling the Role of Angiogenesis in Cancer Ecosystems. Front. Oncol. 2018, 8, 248Azad, T.; Ghahremani, M.; Yang, X. The Role of YAP and TAZ in Angiogenesis and Vascular Mimicry. Cells 2019, 8, E407.Elaimy, A.L.; Mercurio, A.M. Convergence of VEGF and YAP/TAZ Signaling: Implications for Angiogenesis and Cancer Biology. Sci. Signal. 2018, 11, eaau1165.Frezzetti, D.; Gallo, M.; Maiello, M.R.; D’Alessio, A.; Esposito, C.; Chicchinelli, N.; Normanno, N.; De Luca, A. VEGF as a Potential Target in Lung Cancer. Expert Opin. Ther. Targets 2017, 21, 959–966.Elaimy, A.L.; Guru, S.; Chang, C.; Ou, J.; Amante, J.J.; Zhu, L.J.; Goel, H.L.; Mercurio, A.M. VEGF-Neuropilin-2 Signaling Promotes Stem-like Traits in Breast Cancer Cells by TAZ-Mediated Repression of the Rac GAP Β2-Chimaerin. Sci. Signal. 2018, 11, eaao6897.Elaimy, A.L.; Amante, J.J.; Zhu, L.J.; Wang, M.; Walmsley, C.S.; FitzGerald, T.J.; Goel, H.L.; Mercurio, A.M. The VEGF Receptor Neuropilin 2 Promotes Homologous Recombination by Stimulating YAP/TAZ-Mediated Rad51 Expression. Proc. Natl. Acad. Sci. USA 2019, 116, 14174–14180.Xu, C.; Mao, L.; Xiong, J.; Wen, J.; Wang, Y.; Geng, D.; Liu, Y. TAZ Expression on Endothelial Cells Is Closely Related to Blood Vascular Density and VEGFR2 Expression in Astrocytomas. J. Neuropathol. Exp. Neurol. 2019, 78, 172–180.Teleanu, R.I.; Chircov, C.; Grumezescu, A.M.; Teleanu, D.M. Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment. J. Clin. Med. 2019, 9, 84.Lobov, I.; Mikhailova, N. The Role of Dll4/Notch Signaling in Normal and Pathological Ocular Angiogenesis: Dll4 Controls Blood Vessel Sprouting and Vessel Remodeling in Normal and Pathological Conditions. J. Ophthalmol. 2018, 2018, 3565292.Olsen, J.J.; Pohl, S.Ö.-G.; Deshmukh, A.; Visweswaran, M.; Ward, N.C.; Arfuso, F.; Agostino, M.; Dharmarajan, A. The Role of Wnt Signalling in Angiogenesis. Clin. Biochem. Rev. 2017, 38, 131–142Manzat Saplacan, R.M.; Balacescu, L.; Gherman, C.; Chira, R.I.; Craiu, A.; Mircea, P.A.; Lisencu, C.; Balacescu, O. The Role of PDGFs and PDGFRs in Colorectal Cancer. Mediat. Inflamm. 2017, 2017, 4708076Cobbaut, M.; Karagil, S.; Bruno, L.; Diaz de la Loza, M.D.C.; Mackenzie, F.E.; Stolinski, M.; Elbediwy, A. Dysfunctional Mechanotransduction through the YAP/TAZ/Hippo Pathway as a Feature of Chronic Disease. Cells 2020, 9, 151.Low, B.C.; Pan, C.Q.; Shivashankar, G.V.; Bershadsky, A.; Sudol, M.; Sheetz, M. YAP/TAZ as Mechanosensors and Mechanotransducers in Regulating Organ Size and Tumor Growth. FEBS Lett. 2014, 588, 2663–2670.Seo, J.; Kim, J. Regulation of Hippo Signaling by Actin Remodeling. BMB Rep. 2018, 51, 151–156Zhang, C.; Wang, F.; Gao, Z.; Zhang, P.; Gao, J.; Wu, X. Regulation of Hippo Signaling by Mechanical Signals and the Cytoskeleton. DNA Cell Biol. 2020, 39, 159–166Pocaterra, A.; Santinon, G.; Romani, P.; Brian, I.; Dimitracopoulos, A.; Ghisleni, A.; Carnicer-Lombarte, A.; Forcato, M.; Braghetta, P.; Montagner, M.; et al. F-Actin Dynamics Regulates Mammalian Organ Growth and Cell Fate Maintenance. J. Hepatol. 2019, 71, 130–142Matsui, Y.; Lai, Z.-C. Mutual Regulation between Hippo Signaling and Actin Cytoskeleton. Protein Cell 2013, 4, 904–910.Dasgupta, I.; McCollum, D. Control of Cellular Responses to Mechanical Cues through YAP/TAZ Regulation. J. Biol. Chem. 2019, 294, 17693–17706Chang, C.; Goel, H.L.; Gao, H.; Pursell, B.; Shultz, L.D.; Greiner, D.L.; Ingerpuu, S.; Patarroyo, M.; Cao, S.; Lim, E.; et al. A Laminin 511 Matrix Is Regulated by TAZ and Functions as the Ligand for the A6Bβ1 Integrin to Sustain Breast Cancer Stem Cells. Genes Dev. 2015, 29, 1–6.Calvo, F.; Ege, N.; Grande-Garcia, A.; Hooper, S.; Jenkins, R.P.; Chaudhry, S.I.; Harrington, K.; Williamson, P.; Moeendarbary, E.; Charras, G.; et al. Mechanotransduction and YAP-Dependent Matrix Remodelling Is Required for the Generation and Maintenance of Cancer-Associated Fibroblasts. Nat. Cell Biol. 2013, 15, 637–646.Hong, S.-H. Hippo Pathway as Another Oncogenic Mediator to Promote Immune Evasion by PD-L1 Signaling. J. Thorac. Dis. 2019, 11, S318–S321.Ju, X.; Zhang, H.; Zhou, Z.; Wang, Q. Regulation of PD-L1 Expression in Cancer and Clinical Implications in Immunotherapy. Am. J. Cancer Res. 2020, 10, 1–11Janse van Rensburg, H.J.; Azad, T.; Ling, M.; Hao, Y.; Snetsinger, B.; Khanal, P.; Minassian, L.M.; Graham, C.H.; Rauh, M.J.; Yang, X. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1. Cancer Res. 2018, 78, 1457–1470.Lee, B.S.; Park, D.I.; Lee, D.H.; Lee, J.E.; Yeo, M.-K.; Park, Y.H.; Lim, D.S.; Choi, W.; Lee, D.H.; Yoo, G.; et al. Hippo Effector YAP Directly Regulates the Expression of PD-L1 Transcripts in EGFR-TKI-Resistant Lung Adenocarcinoma. Biochem. Biophys. Res. Commun. 2017, 491, 493–499Hsu, P.-C.; Yang, C.-T.; Jablons, D.M.; You, L. The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer. Biomedicines 2018, 6, E114.Yang, W.; Yang, S.; Zhang, F.; Cheng, F.; Wang, X.; Rao, J. Influence of the Hippo-YAP Signalling Pathway on Tumor Associated Macrophages (TAMs) and Its Implications on Cancer Immunosuppressive Microenvironment. Ann. Transl. Med. 2020, 8, 399.Jayasingam, S.D.; Citartan, M.; Thang, T.H.; Mat Zin, A.A.; Ang, K.C.; Ch’ng, E.S. Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice. Front. Oncol. 2019, 9, 1512Zhao, X.; Wang, X.; You, Y.; Wen, D.; Feng, Z.; Zhou, Y.; Que, K.; Gong, J.; Liu, Z. Nogo-B Fosters HCC Progression by Enhancing Yap/Taz-Mediated Tumor-Associated Macrophages M2 Polarization. Exp. Cell Res. 2020, 391, 111979.Huang, Y.-J.; Yang, C.-K.; Wei, P.-L.; Huynh, T.-T.; Whang-Peng, J.; Meng, T.-C.; Hsiao, M.; Tzeng, Y.-M.; Wu, A.T.; Yen, Y. Ovatodiolide Suppresses Colon Tumorigenesis and Prevents Polarization of M2 Tumor-Associated Macrophages through YAP Oncogenic Pathways. J. Hematol. Oncol. 2017, 10, 60Santos-de-Frutos, K.; Segrelles, C.; Lorz, C. Hippo Pathway and YAP Signaling Alterations in Squamous Cancer of the Head and Neck. J. Clin. Med. 2019, 8, 2131Wang, G.; Lu, X.; Dey, P.; Deng, P.; Wu, C.C.; Jiang, S.; Fang, Z.; Zhao, K.; Konaparthi, R.; Hua, S.; et al. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. Cancer Discov. 2016, 6, 80–95.Stampouloglou, E.; Cheng, N.; Federico, A.; Slaby, E.; Monti, S.; Szeto, G.L.; Varelas, X. Yap Suppresses T-Cell Function and Infiltration in the Tumor Microenvironment. PLoS Biol. 2020, 18, e3000591Ni, X.; Tao, J.; Barbi, J.; Chen, Q.; Park, B.V.; Li, Z.; Zhang, N.; Lebid, A.; Ramaswamy, A.; Wei, P.; et al. YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity. Cancer Discov. 2018, 8, 1026–1043Fan, Y.; Gao, Y.; Rao, J.; Wang, K.; Zhang, F.; Zhang, C. YAP-1 Promotes Tregs Differentiation in Hepatocellular Carcinoma by Enhancing TGFBR2 Transcription. Cell Physiol. Biochem. 2017, 41, 1189–1198.Faubert, B.; Solmonson, A.; DeBerardinis, R.J. Metabolic Reprogramming and Cancer Progression. Science 2020, 368, eaaw5473Zhang, X.; Zhao, H.; Li, Y.; Xia, D.; Yang, L.; Ma, Y.; Li, H. The Role of YAP/TAZ Activity in Cancer Metabolic Reprogramming. Mol. Cancer 2018, 17, 134.Santinon, G.; Enzo, E.; Dupont, S. The Sweet Side of YAP/TAZ. Cell Cycle 2015, 14, 2543–2544.Yu, L.; Chen, X.; Sun, X.; Wang, L.; Chen, S. The Glycolytic Switch in Tumors: How Many Players Are Involved? J. Cancer 2017, 8, 3430–3440.Enzo, E.; Santinon, G.; Pocaterra, A.; Aragona, M.; Bresolin, S.; Forcato, M.; Grifoni, D.; Pession, A.; Zanconato, F.; Guzzo, G.; et al. Aerobic Glycolysis Tunes YAP/TAZ Transcriptional Activity. EMBO J. 2015, 34, 1349–1370.Kocemba, K.A.; Dulińska-Litewka, J.; Wojdyła, K.L.; Pękala, P.A. The Role of 6-Phosphofructo-2-Kinase (PFK-2)/Fructose 2,6-Bisphosphatase (FBPase-2) in Metabolic Reprogramming of Cancer Cells. Postepy Hig. I Med. Dosw. (Online) 2016, 70, 938–950.Lin, C.; Xu, X. YAP1-TEAD1-Glut1 Axis Dictates the Oncogenic Phenotypes of Breast Cancer Cells by Modulating Glycolysis. Biomed. Pharmacother. 2017, 95, 789–794.Santinon, G.; Pocaterra, A.; Dupont, S. Control of YAP/TAZ Activity by Metabolic and Nutrient-Sensing Pathways. Trends Cell Biol. 2016, 26, 289–299.Ye, J.; Li, T.-S.; Xu, G.; Zhao, Y.-M.; Zhang, N.-P.; Fan, J.; Wu, J. JCAD Promotes Progression of Nonalcoholic Steatohepatitis to Liver Cancer by Inhibiting LATS2 Kinase Activity. Cancer Res. 2017, 77, 5287–5300.Wang, T.; Frangou, C.; Zhang, J. Fatty Acid Oxidation (FAO) Metabolic Switch: Metastasis in Lymph Nodes Driven by Yes-Associated Protein (YAP) Activation. Biotarget 2019, 3, 13.Bathaie, S.Z.; Ashrafi, M.; Azizian, M.; Tamanoi, F. Mevalonate Pathway and Human Cancers. Curr. Mol. Pharmacol. 2017, 10, 77–85Mullen, P.J.; Yu, R.; Longo, J.; Archer, M.C.; Penn, L.Z. The Interplay between Cell Signalling and the Mevalonate Pathway in Cancer. Nat. Rev. Cancer 2016, 16, 718–731Sorrentino, G.; Ruggeri, N.; Specchia, V.; Cordenonsi, M.; Mano, M.; Dupont, S.; Manfrin, A.; Ingallina, E.; Sommaggio, R.; Piazza, S.; et al. Metabolic Control of YAP and TAZ by the Mevalonate Pathway. Nat. Cell Biol. 2014, 16, 357–366.Zanconato, F.; Battilana, G.; Cordenonsi, M.; Piccolo, S. YAP/TAZ as Therapeutic Targets in Cancer. Curr. Opin. Pharmacol. 2016, 29, 26–33.Kim, M.H.; Kim, J. Role of YAP/TAZ Transcriptional Regulators in Resistance to Anti-Cancer Therapies. Cell. Mol. Life Sci. 2017, 74, 1457–1474Kim, H.-B.; Myung, S.-J. Clinical Implications of the Hippo-YAP Pathway in Multiple Cancer Contexts. BMB Rep. 2018, 51, 119–125.Nguyen, C.D.K.; Yi, C. YAP/TAZ Signaling and Resistance to Cancer Therapy. Trends Cancer 2019, 5, 283–296.Lee, Y.T.; Tan, Y.J.; Oon, C.E. Molecular Targeted Therapy: Treating Cancer with Specificity. Eur. J. Pharmacol. 2018, 834, 188–196Ghiso, E.; Migliore, C.; Ciciriello, V.; Morando, E.; Petrelli, A.; Corso, S.; De Luca, E.; Gatti, G.; Volante, M.; Giordano, S. YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC. Neoplasia 2017, 19, 1012–1021Coggins, G.E.; Farrel, A.; Rathi, K.S.; Hayes, C.M.; Scolaro, L.; Rokita, J.L.; Maris, J.M. YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling. Cancer Res. 2019, 79, 6204–6214Lai, D.; Ho, K.C.; Hao, Y.; Yang, X. Taxol Resistance in Breast Cancer Cells Is Mediated by the Hippo Pathway Component TAZ and Its Downstream Transcriptional Targets Cyr61 and CTGF. Cancer Res. 2011, 71, 2728–2738Muñoz-Galván, S.; Felipe-Abrio, B.; Verdugo-Sivianes, E.M.; Perez, M.; Jiménez-García, M.P.; Suarez-Martinez, E.; Estevez-Garcia, P.; Carnero, A. Downregulation of MYPT1 Increases Tumor Resistance in Ovarian Cancer by Targeting the Hippo Pathway and Increasing the Stemness. Mol. Cancer 2020, 19, 7Kim, M.H.; Kim, C.G.; Kim, S.-K.; Shin, S.J.; Choe, E.A.; Park, S.-H.; Shin, E.-C.; Kim, J. YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma. Cancer Immunol. Res. 2018, 6, 255–266Gong, R.; Yu, F.-X. Targeting the Hippo Pathway for Anti-Cancer Therapies. Curr. Med. Chem. 2015, 22, 4104–4117.Thompson, B.J. YAP/TAZ: Drivers of Tumor Growth, Metastasis, and Resistance to Therapy. Bioessays 2020, 42, e1900162.Oku, Y.; Nishiya, N.; Shito, T.; Yamamoto, R.; Yamamoto, Y.; Oyama, C.; Uehara, Y. Small Molecules Inhibiting the Nuclear Localization of YAP/TAZ for Chemotherapeutics and Chemosensitizers against Breast Cancers. FEBS Open Bio. 2015, 5, 542–549Feng, J.; Gou, J.; Jia, J.; Yi, T.; Cui, T.; Li, Z. Verteporfin, a Suppressor of YAP-TEAD Complex, Presents Promising Antitumor Properties on Ovarian Cancer. OncoTargets Ther. 2016, 9, 5371–5381.Sun, J.; Wang, X.; Tang, B.; Liu, H.; Zhang, M.; Wang, Y.; Ping, F.; Ding, J.; Shen, A.; Geng, M. A Tightly Controlled Src-YAP Signaling Axis Determines Therapeutic Response to Dasatinib in Renal Cell Carcinoma. Theranostics 2018, 8, 3256–3267Hao, F.; Xu, Q.; Wang, J.; Yu, S.; Chang, H.-H.; Sinnett-Smith, J.; Eibl, G.; Rozengurt, E. Lipophilic Statins Inhibit YAP Nuclear Localization, Co-Activator Activity and Colony Formation in Pancreatic Cancer Cells and Prevent the Initial Stages of Pancreatic Ductal Adenocarcinoma in KrasG12D Mice. PLoS ONE 2019, 14, e0216603.Zhao, W.; Liu, H.; Wang, J.; Wang, M.; Shao, R. Cyclizing-Berberine A35 Induces G2/M Arrest and Apoptosis by Activating YAP Phosphorylation (Ser127). J. Exp. Clin. Cancer Res. 2018, 37, 98Jiao, S.; Wang, H.; Shi, Z.; Dong, A.; Zhang, W.; Song, X.; He, F.; Wang, Y.; Zhang, Z.; Wang, W.; et al. A Peptide Mimicking VGLL4 Function Acts as a YAP Antagonist Therapy against Gastric Cancer. Cancer Cell 2014, 25, 166–180Lui, J.W.; Xiao, S.; Ogomori, K.; Hammarstedt, J.E.; Little, E.C.; Lang, D. The Efficiency of Verteporfin as a Therapeutic Option in Pre-Clinical Models of Melanoma. J. Cancer 2019, 10, 1–10.Gibault, F.; Corvaisier, M.; Bailly, F.; Huet, G.; Melnyk, P.; Cotelle, P. Non-Photoinduced Biological Properties of Verteporfin. Curr. Med. Chem. 2016, 23, 1171–1184.Lu, J.; Roy, B.; Anderson, M.; Leggett, C.L.; Levy, M.J.; Pogue, B.; Hasan, T.; Wang, K.K. Verteporfin- and Sodium Porfimer-Mediated Photodynamic Therapy Enhances Pancreatic Cancer Cell Death without Activating Stromal Cells in the Microenvironment. J. Biomed. Opt. 2019, 24, 118001.Gibault, F.; Bailly, F.; Corvaisier, M.; Coevoet, M.; Huet, G.; Melnyk, P.; Cotelle, P. Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo Pathway. ChemMedChem 2017, 12, 954–961.Wang, C.; Zhu, X.; Feng, W.; Yu, Y.; Jeong, K.; Guo, W.; Lu, Y.; Mills, G.B. Verteporfin Inhibits YAP Function through Up-Regulating 14-3-3σ Sequestering YAP in the Cytoplasm. Am. J. Cancer Res. 2016, 6, 27–37.Shi, G.; Wang, H.; Han, H.; Gan, J.; Wang, H. Verteporfin Enhances the Sensitivity of LOVO/TAX Cells to Taxol via YAP Inhibition. Exp. Ther. Med. 2018, 16, 2751–2755Keskin, D.; Sadri, S.; Eskazan, A.E. Dasatinib for the Treatment of Chronic Myeloid Leukemia: Patient Selection and Special Considerations. Drug Des. Dev. Ther. 2016, 10, 3355–3361.Subramaniam, A.; Zheng, J.; Yalamanchili, S.; Conley, A.P.; Ratan, R.; Somaiah, N.; Livingston, J.A.; Zarzour, M.A.; Araujo, D.M.; Benjamin, R.S.; et al. Modulation of YAP/TAZ by Statins to Improve Survival in Epithelioid Hemangioendothelioma (EHE). J. Clin. Oncol. 2020, 38, e23527.Santos, D.M.; Pantano, L.; Pronzati, G.; Grasberger, P.; Probst, C.K.; Black, K.E.; Spinney, J.J.; Hariri, L.P.; Nichols, R.; Lin, Y.; et al. Screening for YAP Inhibitors Identifies Statins as Modulators of Fibrosis. Am. J. Respir. Cell Mol. Biol. 2020, 62, 479–492.Tang, Z.; Ma, Q.; Wang, L.; Liu, C.; Gao, H.; Yang, Z.; Liu, Z.; Zhang, H.; Ji, L.; Jiang, G. A Brief Review: Some Compounds Targeting YAP against Malignancies. Future Oncol. 2019, 15, 1535–1543Morice, S.; Danieau, G.; Rédini, F.; Brounais-Le-Royer, B.; Verrecchia, F. Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers? Cancers 2020, 12, E645.Deng, X.; Fang, L. VGLL4 Is a Transcriptional Cofactor Acting as a Novel Tumor Suppressor via Interacting with TEADs. Am. J. Cancer Res. 2018, 8, 932–943Guo, L.; Teng, L. YAP/TAZ for Cancer Therapy: Opportunities and Challenges (Review). Int. J. Oncol. 2015, 46, 1444–1452Wang, Y.; Hu, G.; Liu, F.; Wang, X.; Wu, M.; Schwarz, J.J.; Zhou, J. Deletion of Yes-Associated Protein (YAP) Specifically in Cardiac and Vascular Smooth Muscle Cells Reveals a Crucial Role for YAP in Mouse Cardiovascular Development. Circ. Res. 2014, 114, 957–965.Daoud, F.; Holmberg, J.; Alajbegovic, A.; Grossi, M.; Rippe, C.; Swärd, K.; Albinsson, S. Inducible Deletion of YAP and TAZ in Adult Mouse Smooth Muscle Causes Rapid and Lethal Colonic Pseudo-Obstruction. Cell Mol. Gastroenterol. Hepatol. 2021, 11, 623–637Schwartzman, M.; Reginensi, A.; Wong, J.S.; Basgen, J.M.; Meliambro, K.; Nicholas, S.B.; D’Agati, V.; McNeill, H.; Campbell, K.N. Podocyte-Specific Deletion of Yes-Associated Protein Causes FSGS and Progressive Renal Failure. J. Am. Soc. Nephrol. 2016, 27, 216–226.Levasseur, A.; St-Jean, G.; Paquet, M.; Boerboom, D.; Boyer, A. Targeted Disruption of YAP and TAZ Impairs the Maintenance of the Adrenal Cortex. Endocrinology 2017, 158, 3738–3753.Dai, Y.; Jablons, D.; You, L. Hippo Pathway in Lung Development. J. Thorac. Dis. 2017, 9, 2246–2250.Lu, L.; Finegold, M.J.; Johnson, R.L. Hippo Pathway Coactivators Yap and Taz Are Required to Coordinate Mammalian Liver Regeneration. Exp. Mol. Med. 2018, 50, e423.León, J.D.; Pareja, A. Inmunología del cáncer II: Bases moleculares y celulares de la carcinogénesis. Horiz. Médico (Lima) 2019, 19, 84–92.Dupont, S.; Morsut, L.; Aragona, M.; Enzo, E.; Giulitti, S.; Cordenonsi, M.; Zanconato, F.; Le Digabel, J.; Forcato, M.; Bicciato, S.; et al. Role of YAP/TAZ in Mechanotransduction. Nature 2011, 474, 179–183ORIGINALPDF.pdfPDF.pdfPDFapplication/pdf13963657https://bonga.unisimon.edu.co/bitstreams/aaffa76f-4475-47d3-b60b-5b0b1b628443/downloadaf1ff5187ee695af002b5ddcdcee391cMD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://bonga.unisimon.edu.co/bitstreams/4f95f664-b3d2-4c78-a4a5-dba97310be47/download4460e5956bc1d1639be9ae6146a50347MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8381https://bonga.unisimon.edu.co/bitstreams/1f5e025a-5f3d-4d7e-8b5b-6f0c1b4212b6/download733bec43a0bf5ade4d97db708e29b185MD53TEXT2021_The_YAPTAZ_Signaling_Pathway.pdf.txt2021_The_YAPTAZ_Signaling_Pathway.pdf.txtExtracted texttext/plain100349https://bonga.unisimon.edu.co/bitstreams/389239b0-8bab-4ded-8560-eac86ae97031/downloadd1783533cb1d1a9ffedda66103eb1e9cMD54PDF.pdf.txtPDF.pdf.txtExtracted texttext/plain100349https://bonga.unisimon.edu.co/bitstreams/6e8ef8e0-f974-48b3-8ddb-5fb1cf69e5e5/downloadd1783533cb1d1a9ffedda66103eb1e9cMD56THUMBNAIL2021_The_YAPTAZ_Signaling_Pathway.pdf.jpg2021_The_YAPTAZ_Signaling_Pathway.pdf.jpgGenerated Thumbnailimage/jpeg6060https://bonga.unisimon.edu.co/bitstreams/790c4a40-c89b-476f-8e69-bceaf71a7afe/download855982823cd0f2932777ffb10b0a7a51MD55PDF.pdf.jpgPDF.pdf.jpgGenerated Thumbnailimage/jpeg6060https://bonga.unisimon.edu.co/bitstreams/31698fad-7253-43ba-b831-d6f5cdb23649/download855982823cd0f2932777ffb10b0a7a51MD5720.500.12442/9506oai:bonga.unisimon.edu.co:20.500.12442/95062024-08-14 21:53:33.708http://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 Internacionalopen.accesshttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.coPGEgcmVsPSJsaWNlbnNlIiBocmVmPSJodHRwOi8vY3JlYXRpdmVjb21tb25zLm9yZy9saWNlbnNlcy9ieS1uYy80LjAvIj48aW1nIGFsdD0iTGljZW5jaWEgQ3JlYXRpdmUgQ29tbW9ucyIgc3R5bGU9ImJvcmRlci13aWR0aDowO3dpZHRoOjEwMHB4OyIgc3JjPSJodHRwczovL2kuY3JlYXRpdmVjb21tb25zLm9yZy9sL2J5LW5jLzQuMC84OHgzMS5wbmciIC8+PC9hPjxici8+RXN0YSBvYnJhIGVzdMOhIGJham8gdW5hIDxhIHJlbD0ibGljZW5zZSIgaHJlZj0iaHR0cDovL2NyZWF0aXZlY29tbW9ucy5vcmcvbGljZW5zZXMvYnktbmMvNC4wLyI+TGljZW5jaWEgQ3JlYXRpdmUgQ29tbW9ucyBBdHJpYnVjacOzbi1Ob0NvbWVyY2lhbCA0LjAgSW50ZXJuYWNpb25hbDwvYT4u |